                               SEQUENCE LISTING

<110> PRIMEVAX IMMUNO-ONCOLOGY, INC.
 
<120> COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE 
      VIRUS AND DENDRITIC CELLS

<130> 48253-702.601

<140>
<141>

<150> 62/231,351
<151> 2015-07-02

<160> 7     

<170> PatentIn version 3.5

<210> 1
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 1
Glu Gly Ser Arg Asn Gln Asp Trp Leu 
1               5                   


<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 2
Thr Ala Tyr Arg Tyr His Leu Leu 
1               5               


<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 3
ggatcccaag aaggggccat                                                   20


<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 4
ggcagctcca tagattgct                                                    19


<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 5
ggtgttgctg cagatggaa                                                    19


<210> 6
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

<400> 6
gtgtcacaga cagtgaggt                                                    19


<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 7
Ser Ile Ile Asn Phe Glu Lys Leu 
1               5               


